Skip to content

Trial · Observational

Not yet recruitingPhase not statedRegistry data

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Short name TIRZ-DOSE-NL

NCTNCT07504172 (opens ClinicalTrials.gov in a new tab)Other id202508
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Not yet recruiting
Phase
Phase not stated
Enrollment
1,700 participants (estimated)
Sponsor
Radboud University Medical Center · Other
Design
Not stated
Countries
1 country

Netherlands

Start
1 Apr 2026 (estimated)
Primary completion
1 Jul 2026 (estimated)
Completion
1 Aug 2026 (estimated)
First posted
31 Mar 2026
Last update posted
31 Mar 2026
Conditions
Overweight , Obesity · Obesity (Disorder)

Timeline

1 trial · 1 not yet recruiting

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
20262027
  1. Ph –

    TIRZ-DOSE-NL

    NCT07504172

    est. 1 Apr 2026 to est. 1 Aug 2026

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice. In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are: * How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching? * How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

Interventions

  • TirzepatideDrug

Arms1

  • Other

    People with obesity

    Adults

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Weight change

    Time frame · Baseline-6 months

    Registry description

    %TWL= (start weight - 6 month weight/baseline weight)\*100%

Secondary outcomes(6)

  1. Changes in body composition

    Time frame · Basline-6 months

    Registry description

    Fat percentage (FP) and fat free mass (FFM)

  2. Demographic and clinical characteristics

    Time frame · Baseline

    Registry description

    * Age * Gender * Treatment location * Obesity associated diseases: hypertension, dyslipidaemia, sleep apnoea and osteoarthritis * Previous lifestyle treatment for obesity

  3. Weight loss by maintenance dose

    Time frame · Baseline-6 months

    Registry description

    Maintenance dose (10mg and 15mg)

  4. Tirzepatide dosing patterns

    Time frame · Baseline-6 months

    Registry description

    Including the initial prescribed dose and subsequent dose escalations throughout the treatment course

  5. Weigth

    Time frame · Baseline-6 months

    Registry description

    in kilograms (kg)

  6. Height

    Time frame · Baseline-6 months

    Registry description

    in centimeters (cm)

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies3

Studies that cite this trial.

Studies with results

3 studies on this page

Indexing hint: Randomized controlled trial · 2025

7 results

Tirzepatide for Obesity Treatment and Diabetes Prevention.

Jastreboff et al. 2025The New England journal of medicinecited by 343

PMID 39536238DOI 10.1056/nejmoa2410819PUB-39536238

Full text at the publisher7 results
Publisher pageSee results (7)

Indexing hint: Systematic review · 2025

13 results

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults.

McGowan et al. 2025Nature medicinecited by 66

PMID 41039116PMC12532627DOI 10.1038/s41591-025-03978-zPUB-41039116

Free to read · publisher termsCC BY-NC-ND13 results
Read at sourceSee results (13)

Indexing hint: Randomized controlled trial · 2022

6 results

Tirzepatide Once Weekly for the Treatment of Obesity.

Jastreboff et al. 2022The New England journal of medicinecited by 2,802

PMID 35658024DOI 10.1056/nejmoa2206038PUB-35658024

Full text at the publisher6 results
Publisher pageSee results (6)

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Adults (age ≥18 years old) * A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia) Exclusion Criteria: * Pregnant women or pregnancy during treatment * Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery) * Patients with diabetes

PepBank is a research reference. Talk to a doctor before you use any peptide.